- Home
- ALEC vs ENTX Comparison
ALEC vs ENTX Comparison
Compare ALEC & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALEC
- ENTX
- Stock Information
- Founded
- ALEC 2013
- ENTX 2010
- Country
- ALEC United States
- ENTX Israel
- Employees
- ALEC N/A
- ENTX N/A
- Industry
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALEC Health Care
- ENTX Health Care
- Exchange
- ALEC Nasdaq
- ENTX Nasdaq
- Market Cap
- ALEC 124.0M
- ENTX 106.4M
- IPO Year
- ALEC 2019
- ENTX 2018
- Fundamental
- Price
- ALEC $1.50
- ENTX $2.55
- Analyst Decision
- ALEC Hold
- ENTX Strong Buy
- Analyst Count
- ALEC 9
- ENTX 1
- Target Price
- ALEC $3.40
- ENTX $10.00
- AVG Volume (30 Days)
- ALEC 4.6M
- ENTX 280.4K
- Earning Date
- ALEC 11-06-2025
- ENTX 11-07-2025
- Dividend Yield
- ALEC N/A
- ENTX N/A
- EPS Growth
- ALEC N/A
- ENTX N/A
- EPS
- ALEC N/A
- ENTX N/A
- Revenue
- ALEC $81,130,000.00
- ENTX $166,000.00
- Revenue This Year
- ALEC N/A
- ENTX N/A
- Revenue Next Year
- ALEC $290.64
- ENTX N/A
- P/E Ratio
- ALEC N/A
- ENTX N/A
- Revenue Growth
- ALEC 46.77
- ENTX 191.23
- 52 Week Low
- ALEC $0.87
- ENTX $1.50
- 52 Week High
- ALEC $6.14
- ENTX $2.95
- Technical
- Relative Strength Index (RSI)
- ALEC 27.08
- ENTX 62.46
- Support Level
- ALEC $1.45
- ENTX $2.12
- Resistance Level
- ALEC $1.60
- ENTX $2.43
- Average True Range (ATR)
- ALEC 0.20
- ENTX 0.22
- MACD
- ALEC -0.20
- ENTX 0.00
- Stochastic Oscillator
- ALEC 8.45
- ENTX 51.81
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.